Oncquest Laboratories Limited - Due diligence report

A 360° intelligence report on Oncquest: trust score, financial health, credit view, compliance, directors, growth and distress signals - gen…

2007-11-29 New Delhi, Delhi Active Unlisted Active Compliant
Share
Connect MCP
OL Oncquest Laboratories Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Oncquest — 360° Intelligence Report

Generated from MCA filings & public records
59/100
Trust Score
Moderate

Oncquest is assessed as Moderate with a Trust Score of 59/100. Oncquest is an active public limited indian non-government company incorporated in 2007, operating in the Healthcare sector. The company has shown revenue growth across its recent filed years. It reported a loss in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and high financial risk profile.

Report generated on 26 Jul 2026 from the latest processed filings. Oncquest Laboratories Limited snapshot & full profile →

Financial Health › Caution
Overall Assessment CautionWeakNeutralGoodStrong Good
Compliance › Good

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreModerate
59/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
68/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreCaution Indicated
25/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
50/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
80/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
65/100
Revenue, profit, asset and hiring momentum.
Distress ScoreCaution Indicated
35/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 50/100 Moderate
  • Negative operating earnings - debt service depends on external support.
  • No open charges - unencumbered balance sheet.
  • Working-capital cover adequate.

Charges position: 0 open (-) · 0 satisfied (-).

Compliance Score: 68/100 Moderate
  • Company status is Active as per MCA.
  • Annual filings current (balance sheet Mar 2025).
  • Litigation present in 2 court forum(s).
  • 2 auditor resignation(s) filed - latest: AGARWAL & AHLUWALIA on 2022-03-01.
  • Delayed payments to MSME suppliers disclosed (3680 disclosure(s)).
  • 2 active GST registration(s).
Legal cases on record (2)
05

Director Intelligence

Stability score: 80/100
NameDIN / PANDesignationAppointedTenureDIN status
ADITYA CHAND BURMAN 01234567 Director 01/04/2018 6 yrs Approved
RAJIV KAPOOR 01234567 Director 01/04/2018 6 yrs Approved
VANDANA WADHWA 01234567 Director 01/04/2018 6 yrs Approved
GAURAV CHAMARIA 01234567 Director 01/04/2018 6 yrs Approved
Naresh Chander Arora 01234567 Director 01/04/2018 6 yrs Approved
Swati Rawat 01234567 Director 01/04/2018 6 yrs Approved
  • 6 directors on the board.
  • No disqualified or deactivated DINs.
  • 6 director exits in 3 years - high churn.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2023)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2023 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
Milky Investment & Trading Co
Subsidiaries
-
Group entities
1
Capital events
3 allotment(s) · 0 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Group entityRelationship% held
Milky Investment & Trading Co Holding Company 74.00%
Puran Associates Private Limited Associate Company 74.00%

Key managerial personnel: VANDANA WADHWA (CFO)

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 65 · Distress 35
Growth signals & trust indicators
Steady revenue growth: +38% over 4 year(s).
EPFO headcount growing - hiring signal.
Operating for 18+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Losses deepening year-on-year.
Outside liabilities up 1.42 in a year.
Negative net worth.
6 director exits within 2 years.
2 auditor resignation(s) on record - review the stated reasons.
MSME payment delays disclosed - latest outstanding 13.17 cr.
2 court case(s) on record - see the legal section for details.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence55/100
Review suggested
Suitability as a supplier / customer counterparty.
  • Check the compliance flags before onboarding.
  • 4 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment47/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • No existing security registered - first-charge position available.
  • Compliance gaps should be priced into terms.
Investor view50/100
Mixed indicators
Growth quality and scalability through an investor lens.
  • 2 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
29 Sep 2025
Last AGM held
Annual general meeting
28 Sep 2025
Director ceased
Naresh Chander Arora
10 Jul 2025
Director ceased
PRASHANT KUMAR BALODIA
16 May 2025
Director appointed
Naresh Chander Arora (Director)
31 Mar 2025
Latest balance sheet
Filed with ROC
12 Feb 2025
Director ceased
Dipanngshu Sannyal
17 Oct 2024
Director appointed
Swati Rawat (Company Secretary)
25 Sep 2024
Director ceased
RAJIV KAPOOR
Director ceased
GAURAV CHAMARIA
23 Sep 2024
Director ceased
ROHIT KATYAL
23 Jan 2024
Director appointed
RAJIV KAPOOR (Director)
26 Oct 2023
Director appointed
GAURAV CHAMARIA (Director)
31 May 2023
Director ceased
PRAHLAD RAI INANI
31 Mar 2022
Securities allotted
23827500 Equity Shares - 23.83 cr raised
01 Mar 2022
Director ceased
ANAND CHAND BURMAN
10

Key Observations

Auto-generated from the data above
Revenue grew 2.1x over the last 4 financial year(s).
Net profit margin moved from 24% to 0.86.
6 active director(s) / partner(s); board looks stable and experienced.
2 active GST registration(s) indicate ongoing business operations.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 3 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Ernakulam Medical Centre U85110KL1980PTC003268 Ernakulam, Kerala, India
Healthmapdiagnostics U85110KA2015PTC079665 Bangalore, Karnataka, India
Hcah U85190DL2012PTC242876 New Delhi, Delhi, India
Kenko U85100MH2020PTC335670 Mumbai, Maharashtra, India
Conner Institute Of Health Care And Research Centre Private Limited U85110DL2004PTC130876 New Delhi, Delhi, India
Connect & Heal U85100DL2015PTC288369 New Delhi, Delhi, India
Tatvacare U72900GJ2020PTC114848 Ahmedabad, Gujarat, India
Cannon Devices Pvt Ltd U32109WB1985PTC039345 Kolkata, West Bengal, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Oncquest before audits and certifications: compliance score 68/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Oncquest: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 50/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Mixed indicators. Growth score 65/100, margin trends, ownership structure and peer set for Oncquest - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Review suggested. Trust score 59/100, distress signals and MSME payment-delay disclosures - know whether Oncquest pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (2 case(s) on record), regulatory flags, charge documents trail and director networks for Oncquest - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Oncquest an active company?

Oncquest has MCA status “Active” with a compliance score of 68/100 (Moderate).

Is Oncquest financially healthy?

Oncquest has a Financial Health Score of 25/100 (Caution Indicated) based on its filed financial statements.

Should I do business with Oncquest?

Its overall Trust Score is 59/100 (Moderate). Vendor verdict: Review suggested. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Oncquest?

The ultimate holding entity is Milky Investment & Trading Co. 6 active director(s) are on record.

Does Oncquest have loans or charges against its assets?

No charges are registered against this company - an unencumbered balance sheet.

Is Oncquest up to date with its ROC filings?

Annual filings current (balance sheet Mar 2025). Overall compliance score: 68/100 (Moderate).

Is it risky to lend to Oncquest?

Its Credit Risk Score is 50/100 (Moderate). Banker verdict: Mixed indicators - deeper appraisal suggested.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.